Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab in Chinese patients with systemic juvenile idiopathic arthritis
ChiCTR-OPB-17013704Phase 4Recruiting
- Sponsor
- Children's Hospital of Chongqing Medical University
- Start
- Jul 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tocilizumab in systemic juvenile idiopathic arthritis (SJIA), sponsored by Children's Hospital of Chongqing Medical University. Primary endpoint: ACR30. Started Jul 2017; status: recruiting.
02
Drugs
tocilizumab
03
Conditions
systemic juvenile idiopathic arthritis (SJIA)
Beyond the preview
Go deeper on ChiCTR-OPB-17013704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPB-17013704.